On December 6, the Board of Pharmacy transitioned to a new payment platform (Gov2Go) for online applications. Additional information about the Iowa eGovernment portal, Gov2Go, was posted later this week. For faster access to Gov2Go, please create a Gov2Go account at web.gov2go.com. If you experience any payment issues while applying for a new license/registration or renewing an existing license/registration, please contact Terry Witkowski.

Also in Iowa, the Department of Public Health (IDPH) posted a NEW Vaccine Information Brief (12.10.21) with update on the vaccine allocation survey on December 13 that  will not include Pfizer Adolescent/Adult Vaccine in order to utilize existing inventory in the state and FDA expands eligibility for Pfizer-BioNTech COVID-19 Booster Dose to Individuals 16 and 17 years of age. Also note last week’s Vaccine Information Brief (12.3.21) announcing ACIP COVID-19 Vaccine Booster Recommendation, Moderna Shelf-Life Extension Update and Updated – Interim Clinical Considerations for Use of COVID-19 Vaccines and this week’s Vaccine Information Brief (12.8.21) with information about Pfizer transition to Comirnaty. Please direct questions to the COVID-19 Vaccine Call Center at 1-800-831-6293 ext. 1 or email.  

Also in Iowa, the Department of Human Services, Iowa Medicaid Enterprise, issued INFORMATIONAL LETTER NO. 2295-MC-FFS announcing the alignment between Managed Medicaid and Medicaid Fee-for-Service to limit the number of diabetic needles that member may obtain per month. The managed care organizations currently allow 100 needles per month. Members enrolled in Medicaid Fee-for-Service were also be limited to 100 diabetic needles per month effective December 1, 2021.  

Finally in Iowa, the Department of Human Services, Iowa Medicaid Enterprise, issued INFORMATIONAL LETTER NO. 2291-MC-FFS announcing several Medicaid Pharmacy Program Changes effective January 1, 2022, related to the following: 

  • Changes to the Preferred Drug List (PDL);  
  • Pharmacy benefit policy changes for albumin human, papaverine injection solution and Zoladex subcutaneous implant;  
  • New Drug Prior Authorization (PA) Criteria for non-biologic agents for ulcerative colitis, Vericiguat (Verquvo) and Viloxazine (Qelbree)  
  • Changes to Existing PA Criteria for Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist, Oral [formerly Elagolix Products], Omalizumab (Xolair) and Topical Acne and Rosacea Products 
  • Point of Sale Billing Updates (ProDUR Quantity Limits) and  
  • DUR Update 

For more information, contact NACDS’ Sandra Guckian at 703-774-4801.